PE20011215A1 - STRATRENS SUBSTITUTED AS SELECTIVELY ACTIVE ESTROGENS - Google Patents

STRATRENS SUBSTITUTED AS SELECTIVELY ACTIVE ESTROGENS

Info

Publication number
PE20011215A1
PE20011215A1 PE2001000335A PE2001000335A PE20011215A1 PE 20011215 A1 PE20011215 A1 PE 20011215A1 PE 2001000335 A PE2001000335 A PE 2001000335A PE 2001000335 A PE2001000335 A PE 2001000335A PE 20011215 A1 PE20011215 A1 PE 20011215A1
Authority
PE
Peru
Prior art keywords
halogen
link
hydrocarbon
substituted
stratrens
Prior art date
Application number
PE2001000335A
Other languages
Spanish (es)
Inventor
Karl-Heinrich Fritzemeier
Christa Hegele-Hartung
Walter Elger
Alexander Hillisch
Uwe Kollenkirchen
Ina Thieme
Vladimir Patchev
Olaf Peters
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20011215A1 publication Critical patent/PE20011215A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic

Abstract

SE REFIERE A DERIVADOS DE ESTRA-1,3,5(10-TRIENO 8ß SUSTITUIDOS DE FORMULA I' DONDE R2 ES H, HALOGENO, R18-O, R18 ES H, HIDROCARBURO C1-C6, TRIFLUOROMETILO, R19SO2-O-; R19 ES R20R21N; R20 Y R21 SON H, ALQUILO C1-C5, COR22; R22 ES HIDROCARBURO C1-C10 OPCIONALMENTE HALOGENADO, CICLOALQUILO C3-C7, ENTRE OTROS; R3 ES R18-O, R19SO2-O, O-COR22, ENTRE OTROS; R6 Y R7 SON H O JUNTOS SON UN ENLACE; R6' Y R7' SON H, HALOGENO, R18-O-, ENTRE OTROS; R8 ES ALQUILO, ALQUENILO C1-C5 OPCIONALMENTE HALOGENADO, ETINILO, PROP-1-INILO; R9 ES H, HIDROCARBURO C1-C5 O JUNTO A R11 ES UN ENLACE; R11 ES H O JUNTO A R12 O R9 SON UN ENLACE; R12 ES H; R11' ES H, HALOGENO, HIDROCARBURO PARCIALMENTE HALOGENADO, ENTRE OTROS; R14 ES ES H O JUNTO A R15 ES UN ENLACE; R15 ES H, O JUNTO A R16 ES UN ENLACE, R15 Y R16 SON H, HALOGENO, R18-O-, ENTRE OTROS; R15' Y R16' SON H, HALOGENO, R18-O-, ENTRE OTROS; R17 Y R17' SON H, H Y HALOGENO; H Y BENCILOXI, ENTRE OTROS; R3 ES OH, METOXI, ACETILO; R2 ES H; R6, R6', R7, R7' SON H; R8 ES METILO, R9 ES H; R9 Y R11 SON JUNTOS UN ENLACE; R11' Y R12 SON H. SON COMPUESTOS PREFERIDOS : 8ß-VINIL-ESTRA-1,3,5(10), 9(11)-TETRAEN-3,17ß-DIOL, ENTRE OTROS. LOS COMPUESTOS PUEDEN SER UTILES PARA EL TRATAMIENTO DE TRASTORNOS PERI U POSTMENOPAUSICOS, PERI U POSTANDROPAUSICOS, TRASTORNOS DE SUENO, IRRITABILIDAD, CAMBIOS DE ANIMO, INCONTINENCIA, ATROFIA VAGINAL, ENFERMEDADES DEL TRACTO UROGENITALREFERS TO DERIVATIVES OF ESTRA-1,3,5 (10-TRIENE 8ß SUBSTITUTED FOR FORMULA I 'WHERE R2 IS H, HALOGEN, R18-O, R18 IS H, HYDROCARBON C1-C6, TRIFLUOROMETHYL, R19SO2-O-; R19 IS R20R21N; R20 AND R21 ARE H, C1-C5 ALKYL, COR22; R22 IS C1-C10 HYDROCARBON OPTIONALLY HALOGENATED, C3-C7 CYCLOALKYL, AMONG OTHERS; R3 IS R18-O, R19SO2-O, O-COR22, AMONG OTHERS; R6 AND R7 ARE HO TOGETHER THEY ARE A LINK; R6 'AND R7' ARE H, HALOGEN, R18-O-, AMONG OTHERS; R8 IS ALKYL, C1-C5 OPTIONALLY HALOGENATED, ETHINYL, PROP-1-YELLOW; R9 IS H , C1-C5 HYDROCARBON OR TOGETHER WITH R11 IS A LINK; R11 IS HO TOGETHER TO R12 OR R9 ARE A LINK; R12 IS H; R11 'IS H, HALOGEN, PARTIALLY HALOGENATED HYDROCARBON, AMONG OTHERS; R14 IS IS HO TOGETHER TO R15 IT IS A LINK; R15 IS H, OR TOGETHER WITH R16 IS A LINK, R15 AND R16 ARE H, HALOGEN, R18-O-, AMONG OTHERS; R15 'AND R16' ARE H, HALOGEN, R18-O-, AMONG OTHERS; R17 AND R17 'ARE H, HY HALOGEN; HY BENZYLOXY, AMONG OTHERS; R3 IS OH, METHYL, ACETYL; R2 IS H; R6, R6', R7, R7 'ARE H; R8 E S METHYL, R9 IS H; R9 AND R11 ARE TOGETHER A LINK; R11 'AND R12 ARE H. PREFERRED COMPOUNDS ARE: 8ß-VINYL-ESTRA-1,3,5 (10), 9 (11) -TETRAEN-3,17ß-DIOL, AMONG OTHERS. THE COMPOUNDS MAY BE USEFUL FOR THE TREATMENT OF PERI OR POSTMENOPAUSAL, PERI OR POSTANDROPAUSIC DISORDERS, SLEEP DISORDERS, IRRITABILITY, MOOD CHANGES, INCONTINENCE, VAGINAL ATROPHY, DISEASES OF THE UROGITAL TRACT

PE2001000335A 2000-04-12 2001-04-11 STRATRENS SUBSTITUTED AS SELECTIVELY ACTIVE ESTROGENS PE20011215A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10019167A DE10019167A1 (en) 2000-04-12 2000-04-12 New 8 beta-substituted 11 beta-(pentyl or hexyl)-estra-1,3,5(10)-triene derivatives, are ovary-selective estrogen receptor ligands useful e.g. as female or male contraceptives or for treating ovarian carcinoma

Publications (1)

Publication Number Publication Date
PE20011215A1 true PE20011215A1 (en) 2001-11-29

Family

ID=7639163

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000335A PE20011215A1 (en) 2000-04-12 2001-04-11 STRATRENS SUBSTITUTED AS SELECTIVELY ACTIVE ESTROGENS

Country Status (11)

Country Link
JP (1) JP4860880B2 (en)
KR (1) KR100825534B1 (en)
AR (1) AR028329A1 (en)
DE (2) DE10019167A1 (en)
PE (1) PE20011215A1 (en)
SI (1) SI1272504T1 (en)
TW (1) TWI288138B (en)
UA (1) UA79073C2 (en)
UY (1) UY26665A1 (en)
YU (1) YU77302A (en)
ZA (1) ZA200209149B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378404B2 (en) * 2000-04-12 2008-05-27 Schering Aktiengesellschaft 8β-hydrocarbyl-substituted estratrienes for use as selective estrogens
DE10151114A1 (en) * 2001-10-15 2003-04-17 Schering Ag New 8 beta-substituted-11 beta-aryl-estra-2,3,5(10)-triene derivatives, are tissue-selective estrogens useful e.g. as female or male contraceptives or for treating ovarian carcinoma
PL1689410T3 (en) * 2003-11-26 2008-10-31 Bayer Schering Pharma Ag Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
US7714012B2 (en) * 2006-11-17 2010-05-11 Trustees Of Dartmouth University Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
EP2014672A1 (en) * 2007-07-12 2009-01-14 Bayer Schering Pharma Aktiengesellschaft 8-beta-substituted estratrienes as selectively active estrogens
CA2744127A1 (en) * 2008-11-21 2010-05-27 Bayer Schering Pharma Aktiengesellschaft Drug delivery system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681407A (en) 1969-06-18 1972-08-01 American Cyanamid Co 3-methoxy 8{62 -methylestra 1,3,5(10),9(11)-tetraene-17{62 -carboxylic acid lower alkyl ester and intermediates in the preparation thereof
US3806546A (en) 1969-06-18 1974-04-23 American Cyanamid Co Steroid-like compounds and method of synthesis
US3736345A (en) 1971-05-18 1973-05-29 American Cyanamid Co Steroid-like compounds and method of synthesis

Also Published As

Publication number Publication date
UY26665A1 (en) 2001-11-30
DE10019167A1 (en) 2001-10-18
JP2003534248A (en) 2003-11-18
SI1272504T1 (en) 2007-10-31
KR20030028734A (en) 2003-04-10
KR100825534B1 (en) 2008-04-25
DE50107204D1 (en) 2005-09-29
JP4860880B2 (en) 2012-01-25
UA79073C2 (en) 2007-05-25
YU77302A (en) 2005-11-28
TWI288138B (en) 2007-10-11
ZA200209149B (en) 2007-10-31
AR028329A1 (en) 2003-05-07

Similar Documents

Publication Publication Date Title
PE55998A1 (en) DERIVATIVES 19-NOR-PREGNENE SUBSTITUTED
CR6861A (en) IMIDAZOL DERIVATIVES
DK0893998T3 (en) Delivery of nicotine into the large intestine for the treatment of inflammatory bowel diseases
AR011480A1 (en) ACIL-ANILIDS SUBSTITUTED WITH CYCLICAL RADICALS (HETERO), NON-STEROIDAL, WITH GESTÁGENA AND MIXED ANDROGENA ACTIVITY.
UY27437A1 (en) CHEMICAL COMPOUNDS
PE20060459A1 (en) AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES AS ß-SECRETASE INHIBITORS
MXPA02010066A (en) 8szlig; HYDROCARBYL SUBSTITUTED ESTRATRIENES FOR USE AS SELECTIVE ESTROGENS.
DE602004011394D1 (en) Thiazolderivate
BR0308394A (en) 5- {2-Hydroxy-3- [1- (3-trifluoromethylphenyl) -cyclopropyl] -propionylamino} -phthalide and progesterone receptor modulating activity-related compounds for use in fertility control and hormone replacement therapy
CA2420576A1 (en) Immunoregulatory compounds, derivatives thereof and their use
AR027059A1 (en) BASES OF INDOLIC MANNICH, PROCEDURE FOR THE PREPARATION, MEDICATIONS CONTAINING THESE COMPOUNDS AND THEIR USE FOR THE PREPARATION OF MEDICINES
DE69130529D1 (en) TREATMENT OF ERECTIONAL FAILURE
BR0007229A (en) Substituted heterocyclic aminoazacycles useful as central nervous system agents
AR029600A1 (en) A PHENOXYACETIC ACID DERIVATIVE, A PHARMACEUTICAL COMPOSITION CONTAINING IT AND USEFUL AGENT FOR THE PREVENTION OF DISEASES, USE OF A PHENOXYACETIC ACID DERIVATIVE FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE PROCESSES OF THE FESTIVAL PROCESS
AU2001272666A1 (en) 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
PE20000055A1 (en) 2,3-SUBSTITUTED INDOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS
AR016667A1 (en) USE OF A COMBINATION OF A MORE PROGESTIN ANTIESTROGEN FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT TO PROVIDE ANTI-CONCEPTION AND A DEANTICONCEPTIVE KIT ADAPTED FOR DAILY ORAL ADMINISTRATION
PE20010541A1 (en) USE OF A BENZIMIDAZOLE COMPOSITION TO TREAT CANCER
PE20011215A1 (en) STRATRENS SUBSTITUTED AS SELECTIVELY ACTIVE ESTROGENS
DE60018569D1 (en) NEW USE OF HYPOOSMOTIC SOLINE SOLUTIONS AND MEDICAMENT BASED THEREFROM
AR034392A1 (en) COMPOUNDS DERIVED FROM 3, 16-DIHIDROXI-ESTRA-1,3,5 (10) -TRIENO, EMPLOYMENT OF THE SAME AND STRUCTURAL PARTS OF THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR018706A1 (en) USE OF A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF VIRAL INFECTIONS
BR0311363A (en) Immediate release pharmaceutical formulation, use thereof, and method for treating a cardiovascular disorder in a patient
ECSP055530A (en) STRATRIENS 9-ALFA-SUBSTITUTED AS SELECTIVE EFFECTIVENESS STRATEGES
DE60128100D1 (en) ANALGICAL DRUG

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed